scholarly journals Modified EPOCH for high‐risk non‐Hodgkin lymphoma in sub‐Saharan Africa

2019 ◽  
Vol 9 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Takondwa Zuze ◽  
Grace K. Ellis ◽  
Edwards Kasonkanji ◽  
Bongani Kaimila ◽  
Richard Nyasosela ◽  
...  
Keyword(s):  
High Risk ◽  
Hodgkin Lymphoma ◽  
Sub Saharan Africa ◽  
Non Hodgkin Lymphoma ◽  
Sub Saharan

scholarly journals Improving outcomes for non‐Hodgkin lymphoma in Sub‐Saharan Africa: where to start?

2020 ◽  
Vol 190 (2) ◽  
pp. 139-140
Author(s):  
Matthew S. Painschab ◽  
Katherine D. Westmoreland ◽  
Tamiwe Tomoka
Keyword(s):  
Hodgkin Lymphoma ◽  
Sub Saharan Africa ◽  
Non Hodgkin Lymphoma ◽  
Sub Saharan

scholarly journals Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Blood ◽  
2012 ◽  
Vol 119 (22) ◽  
pp. 5078-5087 ◽  
Author(s):  
Satish Gopal ◽  
William A. Wood ◽  
Stephanie J. Lee ◽  
Thomas C. Shea ◽  
Kikkeri N. Naresh ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Hodgkin Lymphoma ◽  
Kaposi Sarcoma ◽  
Hematologic Malignancies ◽  
Sub Saharan Africa ◽  
Hematopoietic Stem ◽  
Barr Virus ◽  
Non Hodgkin Lymphoma ◽  
Sub Saharan ◽  
The Impact

Cancer is a leading cause of death and disability in sub-Saharan Africa and will eclipse infectious diseases within the next several decades if current trends continue. Hematologic malignancies, including non-Hodgkin lymphoma, leukemia, Hodgkin lymphoma, and multiple myeloma, account for nearly 10% of the overall cancer burden in the region, and the incidence of non-Hodgkin lymphoma and Hodgkin lymphoma is rapidly increasing as a result of HIV. Despite an increasing burden, mechanisms for diagnosing, treating, and palliating malignant hematologic disorders are inadequate. In this review, we describe the scope of the problem, including the impact of endemic infections, such as HIV, Epstein-Barr virus, malaria, and Kaposi sarcoma–associated herpesvirus. We additionally describe current limitations in hematopathology, chemotherapy, radiotherapy, hematopoietic stem cell transplantation, and supportive care and palliation. We review contemporary treatment and outcomes of hematologic malignancies in the region and outline a clinical service and research agenda, which builds on recent global health successes combating HIV and other infectious diseases. Achieving similar progress against hematologic cancers in sub-Saharan Africa will require the sustained collaboration and advocacy of the entire global cancer community.

scholarly journals Clinical presentation and diagnosis of adult patients with non‐Hodgkin lymphoma in Sub‐Saharan Africa

2020 ◽  
Vol 190 (2) ◽  
pp. 209-221
Author(s):  
Nikolaus C. S. Mezger ◽  
Jana Feuchtner ◽  
Mirko Griesel ◽  
Lucia Hämmerl ◽  
Tobias P. Seraphin ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Clinical Presentation ◽  
Adult Patients ◽  
Sub Saharan Africa ◽  
Non Hodgkin Lymphoma ◽  
Sub Saharan

scholarly journals Mapping the Epidemiology of Kaposi Sarcoma and Non-Hodgkin Lymphoma Among Children in Sub-Saharan Africa: A Review

2016 ◽  
Vol 63 (8) ◽  
pp. 1325-1331 ◽  
Author(s):  
Chris A. Rees ◽  
Elizabeth M. Keating ◽  
Heather Lukolyo ◽  
Heather E. Danysh ◽  
Michael E. Scheurer ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Kaposi Sarcoma ◽  
Sub Saharan Africa ◽  
Non Hodgkin Lymphoma ◽  
Sub Saharan

scholarly journals Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that may promote reproductive health

Microbiome ◽  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Alexander Munoz ◽  
Matthew R. Hayward ◽  
Seth M. Bloom ◽  
Muntsa Rocafort ◽  
Sinaye Ngcapu ◽  
...  
Keyword(s):  
High Risk ◽  
Bacterial Communities ◽  
High Probability ◽  
Temporal Dynamics ◽  
Transition Probabilities ◽  
Low Risk ◽  
Sub Saharan Africa ◽  
Reproductive Outcomes ◽  
Bacterial Composition ◽  
Sub Saharan

Abstract Background Cervicovaginal bacterial communities composed of diverse anaerobes with low Lactobacillus abundance are associated with poor reproductive outcomes such as preterm birth, infertility, cervicitis, and risk of sexually transmitted infections (STIs), including human immunodeficiency virus (HIV). Women in sub-Saharan Africa have a higher prevalence of these high-risk bacterial communities when compared to Western populations. However, the transition of cervicovaginal communities between high- and low-risk community states over time is not well described in African populations. Results We profiled the bacterial composition of 316 cervicovaginal swabs collected at 3-month intervals from 88 healthy young Black South African women with a median follow-up of 9 months per participant and developed a Markov-based model of transition dynamics that accurately predicted bacterial composition within a broader cross-sectional cohort. We found that Lactobacillus iners-dominant, but not Lactobacillus crispatus-dominant, communities have a high probability of transitioning to high-risk states. Simulating clinical interventions by manipulating the underlying transition probabilities, our model predicts that the population prevalence of low-risk microbial communities could most effectively be increased by manipulating the movement between L. iners- and L. crispatus-dominant communities. Conclusions The Markov model we present here indicates that L. iners-dominant communities have a high probability of transitioning to higher-risk states. We additionally identify transitions to target to increase the prevalence of L. crispatus-dominant communities. These findings may help guide future intervention strategies targeted at reducing bacteria-associated adverse reproductive outcomes among women living in sub-Saharan Africa.

Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005–2017

2020 ◽  
pp. 107815522091577 ◽  
Author(s):  
Jennifer R Schenfeld ◽  
Corina W Bennett ◽  
Shuling Li ◽  
Lucy J DeCosta ◽  
Renee R Jaramillo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Febrile Neutropenia ◽  
Hodgkin Lymphoma ◽  
Colony Stimulating Factor ◽  
Myelosuppressive Chemotherapy ◽  
Colony Stimulating Factors ◽  
Non Hodgkin Lymphoma ◽  
Insured Patients ◽  
Stimulating Factor

Purpose Describe temporal changes in use of myelosuppressive chemotherapy, primary prophylactic colony-stimulating factor, and neutropenia-related hospitalization, in commercially insured patients. Methods Using a large commercial administrative database, we identified annual cohorts of adult patients diagnosed with breast or lung cancer, or non-Hodgkin lymphoma and initiating myelosuppressive chemotherapy during 2005–2017. We described yearly changes in proportions of myelosuppressive chemotherapy by febrile neutropenia risk category (high, intermediate, unclassified) and proportion of prophylactic colony-stimulating factor use and unadjusted incidence of neutropenia-related hospitalization in the first cycle of myelosuppressive chemotherapy. Results Annual cohorts included 4383–5888 eligible patients during 2005–2017. The proportion of eligible patients aged ≥ 65 years increased from 26.0% in 2005 to 58.2% in 2017. Myelosuppressive chemotherapy use with regimens with high risk for febrile neutropenia increased from 15.1% in 2005 to 31.0% in 2017; and regimens with intermediate risk for febrile neutropenia decreased from 63.7% to 48.1% in 2017. Prophylactic colony-stimulating factor use increased from 41.6% in 2005 to 54.3% in 2017. Crude incidence of neutropenia-related hospitalization for all cancers increased from 2.0% to 3.1%, with a substantial increase in neutropenia-related hospitalization observed among non-Hodgkin lymphoma patients (2.8% to 8.5%) during 2005–2017. Conclusion Among adult patients with breast and lung cancer, and non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of regimens with high risk for febrile neutropenia increased, as did the use of prophylactic colony-stimulating factors after 2005. Incidence of neutropenia-related hospitalization increased slightly, particularly among non-Hodgkin lymphoma patients. Further studies are required to understand this increasing trend of neutropenia-related hospitalization, changing patient-level risk factors, and febrile neutropenia management.

scholarly journals Time to scale up PrEP beyond the highest-risk populations? Modelling insights from high-risk women in sub-Saharan Africa

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hannah Grant ◽  
Gabriela B. Gomez ◽  
Katharine Kripke ◽  
Ruanne V. Barnabas ◽  
Charlotte Watts ◽  
...  
Keyword(s):  
High Risk ◽  
Scale Up ◽  
Sub Saharan Africa ◽  
High Risk Women ◽  
Sub Saharan
Sign in / Sign up

Export Citation Format

Share Document